In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4492-4496

  Snydman, David R ^a,b   Jacobus, Nilda V ^a   McDermott, Laura A ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CEFOXITIN; CLINDAMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIUM; PROPIONIBACTERIUM ACNES;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTEROIDES FRAGILIS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 57049097734     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00696-08     Document Type: Article

References (14)

1. Ge, Y., M. A. Wikler, D. F. Sahm, R. S. Blosser-Middleton, and J. A. Karlowsky. 2004. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. 48:1384-1396.
2. Golan, Y., L. A. McDermott, N. V. Jacobus, E. J. C. Goldstein, S. M. Finegold, L. Harrell, D. W. Hecht, S. G. Jenkins, C. Pierson, R. Venezia, J. Rihs, Paul Iannini, S. L. Gorbach, and D. R. Snydman. 2003. Emergence of fluoroquinolone resistance among Bacteroides species. J. Antimicrob. Chemother. 52:208-213.
3. Goldstein, E. J. C., D. C. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrell, and H. T. Fernandez. 2008. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob. Agents Chemother. 52:761-766.
4. Holdeman, L. V., and W. E. C. Moore. 1977. Anaerobic laboratory manual, 4th edition. Virginia Polytechnic Institute and State University, Blacksburg.
5. Jones, R. N., H. K. Huynh, and D. J. Biedenbach. 2004. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. 48:3136-3140.
6. Jousimies-Somer, H. R., P. Summanem, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold. 2002. Wadsworth anaerobic bacteriology manual, 6th edition. Star Publishing Co., Belmont, CA.
7. Mikamo, H., K. Izumi, Y. X. Hua, Y. Hyasaki, Y. Sato, and T. Tamaya. 2000. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S04661, against gynaecological pathogens. J. Antimicrob. Chemother. 46:471-474.
8. Mushtaq, S., Y. Ge, and D. Livermore. 2004. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β--lactamases. Antimicrob. Agents Chemother. 48:1313-1319.
9. Mushtaq, S., Y. Ge, and D. Livermore. 2004. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48:3086-3892.
10. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. NCCLS document M11-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. Snydman, D. R., N. V. Jacobus, L. A. McDermott, R. Ruthazer, Y. Golan, E. J. C. Goldstein, S. M. Finegold, L. J. Harrell, D. W. Hecht, S. G. Jenkins, C. Pierson, R. Venezia, V. Yu, J. Rihs, and S. L. Gorbach. 2007. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob. Agents Chemother. 51:1649-1655.
12. Snydman, D. R., N. V. Jacobus, L. A. McDermott, R. Ruthazer, E. Goldstein, S. Finegold, L. Harrell, D. W. Hecht, S. Jenkins, C. Pierson, R. Venezia, J. Rihs, and S. L. Gorbach. 2002. Survey on the susceptibility of B. fragilis group: report and analysis of trends for 1997-2000. Clin. Infect. Dis. 35(Suppl. 1):S126-S134.
13. Snydman, D. R., N. V. Jacobus, L. A. McDermott, R. Ruthazer, E. Goldstein, S. Finegold, L. Harrell, D. W. Hecht, S. Jenkins, C. Pierson, R. Venezia, J. Rihs, and S. L. Gorbach. 2002. In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrob. Agents Chemother. 46:3276-3279.
14. Wexler, H. A., A. E. Engel, D. Glass, and C. Li. 2005. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. 2005. Antimicrob. Agents Chemother. 49:4413-4417.